Logo 1.png
Aeterna Zentaris to Present at the JMP Securities Life Sciences Conference
June 09, 2022 08:00 ET | Aeterna Zentaris Inc
Live video webcast on Wednesday, June 15th at 12:30 PM ET TORONTO, ONTARIO, June 09, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a...
Logo 1.png
Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity
April 11, 2022 08:05 ET | Aeterna Zentaris Inc
– Company to present regarding AIM Biologicals as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD"), an orphan indication with strong unmet medical need ...
Logo 1.png
Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
March 21, 2022 08:05 ET | Aeterna Zentaris Inc
– Company actively monitoring delays to mitigate potential impact of COVID-19 and conflict in Ukraine following Russian invasion on the estimated completion dates for the trial – Patient...
Logo 1.png
Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference
February 07, 2022 08:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Logo 1.png
Aeterna Zentaris Reports Third Quarter 2021 Financial Results and Provides Pipeline Program Updates
November 04, 2021 16:05 ET | Aeterna Zentaris Inc
– Company continues to build strong developmental pipeline – Supported by solid cash position TORONTO, ONTARIO, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS)...
Logo 1.png
Aeterna Zentaris Reports Second Quarter 2021 Financial Results and Provides Pipeline Program Updates
August 04, 2021 16:05 ET | Aeterna Zentaris Inc
– Company continues to advance clinical and preclinical programs with its diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need – Strong...
Logo 1.png
Aeterna Zentaris Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market
August 05, 2020 17:45 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics...
Logo 1.png
AETERNA ZENTARIS ANNOUNCES DISTRIBUTION AGREEMENT WITH MEGAPHARM LTD. TO COMMERCIALIZE MACIMORELIN IN ISRAEL AND THE PALESTINE AUTHORITY
June 25, 2020 08:00 ET | Aeterna Zentaris Inc
CHARLESTON, S.C, June 25, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing...
Robbins Arroyo LLP: Aeterna Zentaris Inc. (AEZS) Misled Shareholders According to a Recently Filed Class Action
November 25, 2014 18:04 ET | Robbins LLP
SAN DIEGO and QUEBEC CITY, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Aeterna Zentaris Inc. (Nasdaq:AEZS) has filed a federal...